Research programme: autoimmune disease therapy - TransTech PharmaAlternative Names: Autoimmune disease therapy research programme - TransTech Pharma
Latest Information Update: 21 Sep 2010
At a glance
- Originator TransTech Pharma
- Class Small molecules
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Autoimmune disorders
Most Recent Events
- 21 Sep 2010 Discontinued - Preclinical for Autoimmune disorders in USA (PO)
- 11 Nov 2004 Early research in Autoimmune disorders in USA (PO)